Opinion|Videos|December 5, 2024
Early Recognition and Use of Biologics to Manage Hidradenitis Suppurativa
Author(s)Jennifer Hsiao, MD, Rani Cooper, MD
Panelists discuss how early recognition of hidradenitis suppurativa coupled with timely initiation of biologic therapies can significantly improve treatment outcomes and prevent disease progression.
Advertisement
Episodes in this series
Advertisement
Related to this article
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Two claims analyses of hidradenitis suppurativa showed similar symptom prevalence in males and females and lower dermatologist access among rural patients than urban patients.
In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.
Advertisement
Advertisement
Trending on Dermatology Times
1
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
2
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
3
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
4
GLP-1 Agonists Address Metabolic Risk in Psoriatic Disease
5